Kimberly A. Robell

980 total citations
8 papers, 500 citations indexed

About

Kimberly A. Robell is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Kimberly A. Robell has authored 8 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in Kimberly A. Robell's work include Cancer Genomics and Diagnostics (2 papers), Cancer-related Molecular Pathways (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Kimberly A. Robell is often cited by papers focused on Cancer Genomics and Diagnostics (2 papers), Cancer-related Molecular Pathways (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). Kimberly A. Robell collaborates with scholars based in United States, United Kingdom and China. Kimberly A. Robell's co-authors include E. Premkumar Reddy, M. V. Ramana Reddy, Stephen C. Cosenza, Anthony D. Kang, Kiranmai Gumireddy, Stacey J. Baker, Muralidhar R. Mallireddigari, Venkat R. Pallela, Melissa Dumble and Shuyun Zhang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Kimberly A. Robell

8 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kimberly A. Robell United States	7	254	160	157	118	107	8	500
Corynn Kasap United States	6	253 1.0×	115 0.7×	214 1.4×	151 1.3×	61 0.6×	12	490
Guobao Zhang United States	9	305 1.2×	102 0.6×	197 1.3×	124 1.1×	154 1.4×	15	594
Harish Nagaraj Singapore	7	190 0.7×	134 0.8×	74 0.5×	113 1.0×	103 1.0×	8	365
Eloisi Caldas-Lopes United States	7	482 1.9×	152 0.9×	84 0.5×	106 0.9×	42 0.4×	11	737
Gretchen A. Repasky United States	8	403 1.6×	200 1.3×	87 0.6×	58 0.5×	47 0.4×	9	634
Rohan Mendonca United States	8	360 1.4×	159 1.0×	130 0.8×	316 2.7×	159 1.5×	8	717
Andrea Uecker Germany	9	207 0.8×	82 0.5×	110 0.7×	56 0.5×	119 1.1×	12	457
Christine Barett Germany	7	215 0.8×	79 0.5×	111 0.7×	85 0.7×	16 0.1×	8	392
Nicolas Warin United Kingdom	4	222 0.9×	115 0.7×	45 0.3×	41 0.3×	111 1.0×	7	394
Tadakazu Akiyama Japan	15	561 2.2×	303 1.9×	116 0.7×	54 0.5×	117 1.1×	17	832

Countries citing papers authored by Kimberly A. Robell

Since Specialization

Citations

This map shows the geographic impact of Kimberly A. Robell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kimberly A. Robell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kimberly A. Robell more than expected).

Fields of papers citing papers by Kimberly A. Robell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kimberly A. Robell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kimberly A. Robell. The network helps show where Kimberly A. Robell may publish in the future.

Co-authorship network of co-authors of Kimberly A. Robell

This figure shows the co-authorship network connecting the top 25 collaborators of Kimberly A. Robell. A scholar is included among the top collaborators of Kimberly A. Robell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kimberly A. Robell. Kimberly A. Robell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Sanborn, Rachel E., Minal Patel, Jordi Rodón, et al.. (2024). 991O First-in-human (FIH) phase I data of HST-1011, an oral CBL-B inhibitor, in patients with advanced solid tumors. Annals of Oncology. 35. S675–S676. 1 indexed citations

Dumbrava, Ecaterina E., Melissa L. Johnson, Anthony W. Tolcher, et al.. (2022). First-in-human study of PC14586, a small molecule structural corrector of Y220C mutant p53, in patients with advanced solid tumors harboring a TP53 Y220C mutation.. Journal of Clinical Oncology. 40(16_suppl). 3003–3003. 58 indexed citations

Dumble, Melissa, Lizhong Xu, Romyr Dominique, et al.. (2021). Abstract LB006: PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development. Cancer Research. 81(13_Supplement). LB006–LB006. 23 indexed citations

Dumble, Melissa, Ming‐Chih Crouthamel, Shuyun Zhang, et al.. (2014). Discovery of Novel AKT Inhibitors with Enhanced Anti-Tumor Effects in Combination with the MEK Inhibitor. PLoS ONE. 9(6). e100880–e100880. 116 indexed citations

Reddy, M. V. Ramana, V. Padmavathi, Muralidhar R. Mallireddigari, et al.. (2011). Discovery of a Clinical Stage Multi-Kinase Inhibitor Sodium (E)-2-{2-Methoxy-5-[(2′,4′,6′-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): Synthesis, Structure–Activity Relationship, and Biological Activity. Journal of Medicinal Chemistry. 54(18). 6254–6276. 76 indexed citations

Lin, Hong, Dennis S. Yamashita, Jin Zeng, et al.. (2009). 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorganic & Medicinal Chemistry Letters. 20(2). 679–683. 8 indexed citations

Reddy, M. V. Ramana, Muralidhar R. Mallireddigari, Stephen C. Cosenza, et al.. (2007). Design, Synthesis, and Biological Evaluation of (E)-Styrylbenzylsulfones as Novel Anticancer Agents. Journal of Medicinal Chemistry. 51(1). 86–100. 46 indexed citations

Gumireddy, Kiranmai, Stacey J. Baker, Stephen C. Cosenza, et al.. (2005). A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proceedings of the National Academy of Sciences. 102(6). 1992–1997. 172 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact